^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Litfulo (ritlecitinib)

    i
    Other names: PF-06651600, PF-6651600, PF 6651600, PF 06651600, PF6651600
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    JAK3 inhibitor, TEC inhibitor
    Related drugs:
    Associations

    News

    Trials
    4d
    Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Pfizer | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    Litfulo (ritlecitinib)
    8d
    BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report. (PubMed, Br J Dermatol)
    The efficacy of ritlecitinib, an oral Janus kinase 3/TEC family inhibitor, has been demonstrated in the Allegro clinical trials...The US Food and Drug Administration issued black box warnings, citing increased risks of major adverse cardiovascular events, malignancies, venous thromboembolism (VTE) and mortality based on data from tofacitinib, baricitinib and upadacitinib in rheumatoid arthritis...The patient received intravenous broad-spectrum antibiotics for sepsis of unknown origin, hydrocortisone and vasopressor support for hypotension. She was anticoagulated with dalteparin and transitioned to apixaban as per respiratory advice for unprovoked pulmonary emboli...This case highlights a probable severe adverse event associated with ritlecitinib therapy, including pulmonary emboli and infection of unidentified source, associated with new-onset atrial fibrillation and acute kidney injury in a patient without known risk factors for VTE. Ongoing pharmacovigilance is essential to understand the potential risks associated with Janus kinase inhibitors in AA treatment.
    Journal
    |
    JAK3 (Janus Kinase 3) • CRP (C-reactive protein)
    |
    tofacitinib • Fragmin (dalteparin sodium) • Litfulo (ritlecitinib)
    25d
    B7981119: A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (clinicaltrials.gov)
    P2, N=240, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Litfulo (ritlecitinib)
    29d
    A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice. (clinicaltrials.gov)
    P=N/A, N=3000, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Mar 2030 | Trial primary completion date: Sep 2030 --> Mar 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Litfulo (ritlecitinib)
    1m
    Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission (clinicaltrials.gov)
    P2, N=40, Recruiting, Massachusetts General Hospital | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Litfulo (ritlecitinib)
    1m
    A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Pfizer
    New P2 trial
    |
    Litfulo (ritlecitinib)
    1m
    A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. (clinicaltrials.gov)
    P2, N=200, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Litfulo (ritlecitinib)
    1m
    Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Pfizer
    New trial • Real-world evidence
    |
    Litfulo (ritlecitinib)
    2ms
    Designing new hit series of JAK3 inhibitors using generative AI, reinforcement learning, and molecular dynamics. (PubMed, Comput Biol Med)
    In a benchmark for ritlecitinib, we found that scaffolds NS_1813 and NS_2063 showed better binding affinities, with 20 compounds meeting our selection criteria...From these, six lead compounds were chosen for detailed molecular dynamics and docking pose analyses to assess their conformational stability and binding interactions within the JAK3 active site. These compounds are promising candidates for further development, including chemical synthesis, followed by in vitro and in vivo testing to evaluate their potential as JAK3-targeting therapeutic agents.
    Journal
    |
    JAK3 (Janus Kinase 3)
    |
    Litfulo (ritlecitinib)
    2ms
    A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Pfizer
    New P2 trial
    |
    Litfulo (ritlecitinib)
    2ms
    Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. (PubMed, Dermatol Ther (Heidelb))
    NCT06873945. Video Abstract (MP4 303790 kb).
    Clinical • P3 data • Journal
    |
    JAK3 (Janus Kinase 3)
    |
    Litfulo (ritlecitinib)
    3ms
    B7981028: A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. (clinicaltrials.gov)
    P3, N=140, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Litfulo (ritlecitinib)